Veeva Systems Cl A saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.
The new score means the company is now outperforming 98% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
Veeva Systems Cl A is currently forming a cup without handle, with a 258.93 buy point. Look for the stock to break out in volume at least 40% higher than normal.
Discover The 3 Keys To Successful Stock Investing
The stock sports a 97 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 97% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company posted a 26% earnings gain for Q4. Top line growth rose 14%, up from 13% in the prior report. That marks one quarter of increasing revenue growth.
Veeva Systems Cl A holds the No. 4 rank among its peers in the Computer Software-Medical industry group. Doximity is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
